Abstract
Investigating the genetic factors influencing human birth weight may lead to biological insights into fetal growth and long-term health. Genome-wide association studies of birth weight have highlighted associated variants in more than 200 regions of the genome, but the causal genes are mostly unknown. Rare genetic variants with robust evidence of association are more likely to point to causal genes, but to date, only a few rare variants are known to influence birth weight. We aimed to identify genes that harbour rare variants that impact birth weight when carried by either the fetus or the mother, by analysing whole exome sequence data in UK Biobank participants.
We annotated rare (minor allele frequency <0.1%) protein-truncating or high impact missense variants on whole exome sequence data in up to 234,675 participants with data on their own birth weight (fetal variants), and up to 181,883 mothers who reported the birth weight of their first child (maternal variants). Variants within each gene were collapsed to perform gene burden tests and for each associated gene, we compared the observed fetal and maternal effects. We identified 8 genes with evidence of rare fetal variant effects on birth weight, of which 2 also showed maternal effects. One additional gene showed evidence of maternal effects only. We observed 10/11 directionally concordant associations in an independent sample of up to 45,622 individuals (sign test P=0.01).
Of the genes identified, IGF1R and PAPPA2 (fetal and maternal-acting) have known roles in insulin-like growth factor bioavailability and signalling. PPARG, INHBE and ACVR1C (all fetal-acting) have known roles in adipose tissue regulation and rare variants in the latter two also showed associations with favourable adiposity patterns in adults. We highlight the dual role of PPARG in both adipocyte differentiation and placental angiogenesis. NOS3, NRK, and ADAMTS8 (fetal and maternal-acting) have been implicated in both placental function and hypertension.
Analysis of rare coding variants has identified regulators of fetal adipose tissue and fetoplacental angiogenesis as determinants of birth weight, as well as further evidence for the role of insulin-like growth factors.
Competing Interest Statement
J.R.B.P. and E.J.G. are employees/shareholders of Insmed. J.R.B.P. also receives research funding from GSK. Y.Z. is a UK University worker at GSK. S.O. has undertaken remunerated consultancy work for Pfizer, Third Rock Ventures, AstraZeneca, NorthSea Therapeutics and Courage Therapeutics. V.S., V.T., T.O., G.T., and K.S. are employees of deCODE genetics, a subsidiary of Amgen.
Funding Statement
B.E.M.L., R.N.B. and R.M.F. were supported by a Wellcome Senior Research Fellowship (WT220390). This research was funded in part by the Wellcome Trust (WT220390). R.M.F. is also supported by a grant from the Eunice Kennedy Shriver National Institute Of Child Health & Human Development of the National Institutes of Health under Award Number R01HD101669. K.A.K., L.R.K., E.J.G., Y.Z., F.R.D., K.K.O. and J.R.B.P. are supported by the Medical Research Council (MC_UU_00006/2). This study was supported by the National Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre and the NIHR Cambridge Comprehensive Biomedical Research Centre. The views expressed are those of the authors and not necessarily those of the NIHR or the Department of Health and Social Care. For the purpose of open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This research has been conducted using the UK Biobank Resource under Application Numbers 9905 and 7036. UK Biobank data has approval from the North West Multi-centre Research Ethics Committee (MREC) as a Research Tissue Bank (RTB). Use of the Icelandic data was approved by the National Bioethics Committee (VSN-15-169). All genotyped participants signed a written informed consent allowing the use of their samples and data in projects at deCODE genetics approved by the NBC. Data were anonymized and encrypted by a third-party system, approved and monitored by the Icelandic Data Protection Authority.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data availability
UK Biobank data are available on application via https://www.ukbiobank.ac.uk/enable-your-research/register.
